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Abstract
Background: Mollicutes contamination is recognized to be a critical issue for the cultivation of continuous cell
lines. In this work we characterized the effect of Mycoplasma hyorhinis contamination on CD133 expression in
human colon cancer cell lines.
Methods: MycoAlert® and mycoplasma agar culture were used to detect mycoplasma contamination on GEO,
SW480 and HT-29 cell lines. Restriction fragment length polymorphism assay was used to determine mycoplasma
species. All cellular models were decontaminated by the use of a specific antibiotic panel (Enrofloxacin,
Ciprofloxacin, BM Cyclin 1 and 2, Mycoplasma Removal Agent and MycoZap®). The percentage of CD133 positive
cells was analyzed by flow cytometry on GEO, SW480 and HT-29 cell lines, before and after Mycoplasma hyorhinis
eradication.
Results: Mycoplasma hyorhinis infected colon cancer cell lines showed an increased percentage of CD133+ cells as
compared to the same cell lines rendered mycoplasma-free by effective exposure to antibiotic treatment. The
percentage of CD133 positive cells increased again when mycoplasma negative cells were re-infected by
Mycoplasma hyorhinis.
Conclusions: Mycoplasma hyorhinis infection has an important role on the quality of cultured human colon cancer
cell lines giving a false positive increase of cancer stem cells fraction characterized by CD133 expression. Possible
explanations are (i) the direct involvement of Mycoplasma on CD133 expression or (ii) the selective pressure on a
subpopulation of cells characterized by constitutive CD133 expression.
In keeping with United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines, the present
data indicate the mandatory prerequisite, for investigators involved in human colon cancer research area, of
employing mycoplasma-free cell lines in order to avoid the production of non-reproducible or even false data.
Background
It is well-known that mycoplasma can have adverse
effects on cell cultures such as altered levels of protein
and of RNA/DNA synthesis, induction of chromosomal
aberrations, changes in cell membrane composition and
modification of cellular morphology [1,2]. Furthermore,
mycoplasma contamination can interfere with a number
of biological parameters, thus influencing final data of
experimental investigations [1,2].
Since human continuous cell lines derived from solid
tumors are often used to explore biological and func-
tional alterations of tumor cells, the use of mycoplasma-
free cell cultures for research and specifically in isolating
cancer stem cells (CSCs) is mandatory [3].
The aim of this study is to show how and to what
extent the expression of CD133 antigen can be altered
by Mycoplasma hyorhinis contamination. To address
this issue, we employed the well-established GEO,
SW480 and HT-29 human colon cell lines [4-6] and
multidimensional flow cytometry.
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screened the colon cancer cell lines both for a putative
Mollicutes contamination [7,8] and for CD133 expres-
sion [9,10]. In spite of a bright positivity for CD133 anti-
gen during Mycoplasma hyorhinis contamination, after
antibiotic decontamination it was possible to evidence a
decrease in the percentage of CD133 positive cellular
population. On these bases we decided to demonstrate
that Mollicutes agents can have remarkable effects on
the correct identification and characterization of CD133
positive CSCs subpopulation.
Methods
Cell Culture
Human colon cancer continuous cell lines were
obtained from a research laboratory at CEINGE, Biotec-
nologie Avanzate (Naples, Italy). In particular, GEO,
SW480 and HT-29 cell lines were cultured in DMEM,
RPMI 1640 and McCoy’s 5A Medium Modified (Sigma-
Aldrich Corporation, St. Louis, Missouri, USA) respec-
tively, 10% foetal bovine serum (FBS; Hyclone, Logan,
UT, USA) and 1% Ultraglutamine 1 (Lonza Verviers,
Belgium). All cell lines were grown in T-75 flasks (Corn-
ing Incorporated, New York) in humidified atmosphere
of air containing 5% CO2 until complete confluence,
they were then detached by trypsin/EDTA (Sigma-
Aldrich Corporation, St. Louis, Missouri, USA). During
the study, all cell cultures were periodically tested for
the absence of bacteria and fungi contaminations by the
BacT/ALERT® 3D (bioMérieux INDUSRTY, Hazelwood,
MO, USA) instrument, an automated microbial detec-
tion system. As regards mycoplasma detection, the cell
lines were cultured in absence of antibiotics for at least
2 weeks after thawing and samples were taken after a
culture period of at least 2 or 7 days without medium
exchange, as suggested by CC Uphoff and HG Drexler
[7].
Flow Cytometry
After enzymatic detachment from saturated cultures,
GEO, SW480 and HT-29 cell lines were studied for
CD133 expression (anti-CD133/1-PE; AC133 clone; Mil-
tenyi Biotec, Auburn, CA, USA). For each sample the
respective control was prepared in order to determine
the level of background cellular autofluorescence with-
out antibody staining. All samples were incubated for 20
minutes at 4°C, washed twice with PBS (Sigma-Aldrich
Corporation, St. Louis, Missouri, USA) and finally ana-
lyzed using a FACSAria flow cytometer and the FACS-
Diva software (Becton Dickinson, Franklin Lakes, NJ).
Cells were first gated on physical parameters (FSC and
SSC) to exclude the majority of debris and dead cells.
Afterwards, an FSC-Area vs FSC-Height dot plot was
used to identify single cells and exclude doublets.
Putative CSCs and immature cells were gated in a
CD133 vs empty channel (FITC) dot plot.
Mycoplasma Detection
During the study, supernatants of GEO, SW480 and
HT-29 cell lines were collected and tested with the
MycoAlert® mycoplasma detection kit (Lonza Verviers,
Belgium) using the MycoAlert® assay control set (Lonza
Verviers, Belgium), as suggested by the manufacturer’s
instructions.
All the samples were also tested by the microbiologi-
cal aerobic and anaerobic agar culture.
Mycoplasma agar and broth were used as media for
the detection of all mycoplasma species and were pre-
pared according to the manufacturer’s instructions
(Oxoid, Hampshire, England). In particular, the myco-
plasma agar was obtained by dissolving 2.84 grams of
mycoplasma agar base (Oxoid, Hampshire, England) in
80 ml of distilled water and sterilized by autoclaving at
121°C for 15 minutes. After cooling, it was combined
with 20 ml of mycoplasma selective supplement-G
(Oxoid, Hampshire, England) and dispensed into Petri
plates. In order to prepare the mycoplasma broth, 2.04
grams of mycoplasma broth base (Oxoid, Hampshire,
England) were dissolved in 80 ml of distilled water and
sterilized by autoclaving at 121°C for 15 minutes. After
cooling, the mycoplasma broth was mixed with 20 ml of
mycoplasma selective supplement-G (Oxoid, Hampshire,
England) and, finally, aliquots of mycoplasma broth
were imparted into tubes.
Therefore, cell culture supernatant test samples
(100 μl) were pipetted onto the mycoplasma agar plates
and incubated anaerobically for 14 days at 37°C. Ali-
quots (100 μl) of the same test sample were incubated
in mycoplasma broth; after a 14 days aerobic incubation,
aliquots of 100 μl were subcultured onto mycoplasma
agar for 14 days in anaerobic conditions. Development
of typical mycoplasma colonies, characterized by a “fried
egg” appearance, was observed under the inverted
microscope.
Mycoplasma Species Determination
Mycoplasma positive GEO, SW480 and HT-29 cell lines
were cultured for 7 days without antibiotics. One ml of
each cell culture supernatant was centrifuged for 10
minutes at 13000 g at 4°C. The obtained pellets were
washed twice with PBS (Sigma-Aldrich Corporation, St.
Louis, Missouri, USA) and incubated for 15 minutes at
95°C. Mycoplasmatic DNA was extracted and purified
using the Nucleon BACC2 kit (Amersham Biosciences,
Freiburg, Germany). As recommended by CC Uphoff
and HG Drexler [11], the PCR was performed in a final
volume of 50 μl containing 100 μMo fe a c hd e o x y n u -
cleotide, 1.5 μMM g C l 2,1 . 2 5UJ u m pS t a r tT a qD N A
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souri, USA) and 0,2 μM of each primer. The PCR pro-
ducts were subjected to the restriction fragment length
polymorphism assay. In particular, the amplicons were
digested for 1 hour at 37°C in a final volume of 20 μl
with the restriction endonucleases AspI, XbaI, HpaII,
and HaeIII (Roche Diagnostic, Mannheim, Germany).
Restriction fragments were then analyzed on a 1.5%
agarose gel and visualized by ethidium bromide staining.
The fragments polymorphism pattern identified the
mycoplasma contaminant species [11].
Mycoplasma Decontamination
Mycoplasma eradication was accomplished by the anti-
biotic treatment of the infected GEO, SW480 and HT-
29 cell lines. Of note, we utilized the three classes of
antibiotics that were shown to be highly effective against
mycoplasmas [12]. In fact, quinolones inhibit DNA
replication, whereas tetracyclines and macrolides ham-
per protein synthesis [12].
In particular, infected cells were treated with the qui-
nolones enrofloxacin (Fluka, BioChemika, distributed by
Sigma-Aldrich Corporation, St. Louis, Missouri, USA)
and Mycoplasma Removal Agent (Euroclone, Lugano,
Switzerland) at concentration of 25 μg/ml and 0.5 μg/ml,
respectively, for 7 days. Cells were also exposed to the
quinolone ciprofloxacin (Fluka, BioChemika, distributed
by Sigma-Aldrich Corporation, St. Louis, Missouri,
USA) at the concentration of 10 μg/ml for 14 days.
Moreover, the anti-micoplasmatic treatment, included
the BM Cyclin 1 (Roche, Mannheim, Germany), con-
taining the macrolide tiamulin, for 3 days at the final
concentration of 10 μg/ml, followed by the BM Cyclin 2
(Roche, Mannheim, Germany), containing the tetracy-
cline minocycline, for 4 days at the concentration of
5 μg/ml.
Finally, MycoZap® mycoplasma elimination reagent
(Lonza Verviers, Belgium) was used. The kit includes a
combination of antibiotic and antimetabolic agents
protected by a patent. MycoZap® reagent 1 was used for
4 days, while reagent 2 was used for 12 days, according
to the manufacturer’s data sheet.
As for mycoplasma detection, all antibiotic-treated cell
lines were cultured for at least 4 weeks without any che-
motherapic molecules.
Co-cultivation of Mycoplasma with Cell Cultures
Approximately 80% confluent monolayer of myco-
plasma-eradicated GEO cell line was used for the Myco-
plasma hyorhinis-driven infection. The growth of the
Mycoplasma hyorhinis was carried out using the media
and culture conditions recommended by the supplier
(ATCC, Rockville, MD).
On the day of infection, the old medium was replaced
with fresh medium containing the dilution of viable
mycoplasma at a concentration of about 10 CFU/ml,
previously determined by the microbiological aerobic
and anaerobic agar culture. The infected cells were then
incubated at 37°C, 5% CO2.E v e r y7d a y s ,s u p e r n a t a n t s
were tested for mycoplasma detection and, in case of
positive result the cells were detached with trypsin/
EDTA and processed for cytometric analysis.
Results and Discussion
Mollicutes contamination is recognized to be a critical
issue for the cultivation of continuous cell lines and
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Figure 1 Determination of the mycoplasma species by restriction fragment length polymorphisms analysis of PCR products.T h e
fragment pattern identifies the contaminant as Mycoplasma hyorhinis.
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Page 3 of 6about 30% of all cellular models are reported as myco-
plasma-infected with a limited number of human species
origin [11]. It is well-known that Mollicutes agents can
heavily interfere with cellular activities such as growth
r a t e ,D N A ,R N Aa n dp r o t e i ns y n t h e s i sa sw e l la sc a u s e
significant cell morphology alterations [13-16]. Consid-
ering that one of the main objectives of our research
project was the characterization and isolation of CD133-
positive CSCs in human cellular models, we carefully
checked the employed cell lines to detect Mollicutes
agent contamination as indicated by good tissue culture
practice.
MycoAlert® assay [8] showed that GEO, HT-29 and
SW480 cell lines were positive to Mollicutes agent con-
tamination, being the B/A score of 62, 53 and 16,
respectively (data not shown). Later on, these results
were confirmed by aerobic and anaerobic microbiological
agar culture (data not shown). In order to determine
the contaminant species, we performed the analysis of
modified restriction fragment length polymorphisms.
The application of this method revealed that GEO,
SW480 and HT-29 cell lines were infected by
Mycoplasma hyorhinis, one of the most common cell
culture contaminants encountered [17] (Figure 1).
Although in the past, this cell culture contaminant was
thought to derive from bovine sera, nowadays FBS is
tested for mycoplasma contamination and therefore
microrganisms are more likely to spread from one cell
culture to another by inadequate cell culture techniques
[17].
Cell lines for CD133 expression were then character-
ized (Figure 2). A negative control was prepared for
each sample in order to determine the level of back-
ground cellular autofluorescence without antibody
Mycoplasma 
free SW480
Mycoplasma 
free GEO
Mycoplasma 
free HT-29
C
2.3%
0.2%
75.6% 92.5%
Mycoplasma 
positive HT-29 
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Mycoplasma
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Figure 2 Cytometric analysis of CD133 expression in GEO, SW480 and HT-29 cell lines. Panel A shows control cells without antibody.
Panel B shows Mycoplasma hyorhinis-positive cells. Panel C shows mycoplasma-free cells.
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Page 4 of 6staining (Figure 2, Panel A). We observed the clear-cut
separation of a CD133+ population, that was equal to
5.7%, 52.5% and 92.5% in case of GEO, SW480 and HT-
29 Mycoplasma contaminated cell lines, respectively
(Figure 2, Panel B).
All cell lines underwent the eradication protocol and
were successfully decontaminated by BM Cyclin 1 and 2
treatment. After the combined use of MycoAlert® and
microbiological agar culture detection assay showing the
absence of the contaminant, the three cell lines for
CD133 expression were screened in a new cytometric
set of experiments. As shown in Figure 2, Panel C, a
remarkable CD133 expression decrease was observed
resulting in 2.3%, 0.2% and 75.6% in case of GEO,
SW480 and HT29, respectively.
In order to confirm the ability of Mycoplasma hyorhi-
nis to increase the percentage of CD133+ cells in
human colon cancer cell lines, we re-infected GEO cells
and checked the cell culture supernatant by MycoAlert®
analysis once a week. The results of this experiment
showed that Mycoplasma hyorhinis was detectable only
after 21 days of co-incubation with GEO cells at 37°C
and 5%CO2. For each step of the experiment, the
respective negative control was prepared in order to
determine the level of background cellular autofluores-
cence without antibody staining (Figure 3, panel A). As
shown in panel B and C of Figure 3, cytometric analysis
demonstrated a significant (P = 0,0286, Mann-Whitney
test) increase of CD133+ population in Mycoplasma
hyorhinis positive GEO cells compared to the same
Figure 3 Cytometric analysis of CD133 expression in GEO at different post-infection time. Panel A shows GEO cells without antibody.
Panel B shows mycoplasma-free GEO cells. Panel C shows Mycoplasma hyorhinis-positive GEO cells.
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Page 5 of 6microorganism-free GEO control cells. In fact, 3.4%,
4.3%, 26.5% and 37.2% CD133+ cells were detected on
days 21, 28, 49 and 56 post infection respectively,
whereas 0.3%, 0.7%, 0.8% and 0.9% were found on days
21, 28, 49 and 56 respectively, in mycoplasma-free con-
trol cells.
Conclusions
Our results demonstrate that Mycoplasma hyorhinis
infection can play an important role on cultured human
colon cancer cell lines giving rise to considerable false
positive increase of CSCs cellular fraction characterized
by CD133 expression. This occurrence may be explained
by: i) the direct influence of mycoplasma on anti-CD133
MoAb binding sites or ii) the ability of CD133 positive
cells to survive despite the toxic effects exerted by the
mycoplasma.
In conclusion, methods for the detection, elimination
and prevention of Mollicutes contamination should be
included in the basic panel of CSCs research techniques.
We are confident that technical advancements in cell
lines handling will facilitate CSCs studies, positively
influencing oncological research improvement in the
near future.
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